Brazil seized unregistered weight-loss peptide pens sold as 'research' chemicals

On 6 October 2026 Brazil's health regulator Anvisa published a resolution in the Diário Oficial da União ordering the immediate seizure and suspension of sale, distribution, manufacture, advertising and use of multiple unapproved weight-loss pens and injectable peptides sold online as 'research' chemicals but marketed for human consumption.

The federal action named the 60 mg Tirzegen tirzepatide pens and 40 mg Retagen retatrutide pens manufactured by Oxygen Pharm, a 40 mg retatrutide product from Alluvi Healthcare, and compounds such as PC-157 & TB-500, NAD+ and GLOW GHK-Cu from brands including Oxygen KW Pharma and Synedica Labs, promoted through storefronts like Peptídeos do Brasil and Peptídeos Pro. Anvisa found clear evidence of direct human administration despite the research-only labels.

The health logic was blunt: home-diluted injectables bypass sterile manufacturing, creating direct pathways to severe bacterial infections, abscesses and systemic sepsis — a trend highlighted after consumers began buying raw tirzepatide powder online and mixing it in home kitchens. The sweep extended earlier enforcement that blocked gopharma.shop and its T.G., Tirzec and Lipoless MD pens and the T36 injectable; retatrutide holds no regulatory approval in any country. Poder360 contacted the named companies for comment and received no statements.

Products ordered seized and pulled from sale, distribution, manufacture and advertising across all physical and digital channels in Brazil; no fines reported yet

The pens had no registration, no clinical trials and unknown manufacturing origin — nothing a regulator could approve.

Storefronts labelled vials 'research only' while marketing them for weight loss, which reads as evasion, not labelling.

Home dilution of raw tirzepatide powder outside sterile facilities created sepsis-grade contamination risk.

Retatrutide has no regulatory approval in any country, so there was no lawful pathway for these products at all.

A 'for research use only' label is not a business model: regulators treat evidence of human marketing as exactly what it is, and seize the stock.

Anvisa's administrative and law-enforcement actions remain active, with federal inspectors monitoring domestic distribution channels for continued non-compliance. No fines or company statements were reported as of the source date.